In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals In Depth: June/July 2013

Executive Summary

In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.

You may also be interested in...



NICE Decision On Arthritis Opens Door For Biosimilars In England

A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

Granules Records Double-Digit Growth On The Back Of New Launches

India’s Granules has grown through increased market penetration of its existing products as well as new product launches. The company is planning to invest in expanding its API capacity, finished dosages and a new multiple unit pellet facility.

EU Business Round-Up: Probi Signs Oriflame Deal, Holland & Barrett Heads To China, Enzymatica Launches On Amazon

The latest European health & wellness business news: Probi partners with Swedish beauty firm Oriflame for probiotic launch; retailer Holland & Barrett enters the Chinese market with Alibaba's Tmall; and Enzymatica sees ColdZyme growth potential on Amazon.

Topics

Related Companies

UsernamePublicRestriction

Register

IV004095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel